Individuals with schizophrenia (SZ) display cognitive deficits that have been identified as major determinants of poor functioning and disability, representing a serious public health concern and an important target for interventions. At present, available treatments offer only minimal to moderate benefits to ameliorate cognitive deficits. Thus, there remains an urgent need to identify novel interventions to improve cognition in people with SZ. Emerging evidence from animal and basic human research suggests aerobic exercise training (AE) has beneficial effects on cognition.
Furthermore, in a recent meta-analysis of SZ studies, Ahmed et al. [31] found higher peripheral BDNF levels significantly correlated with better performance on reasoning and problem-solving tasks. Thus, BDNF upregulation may lead to improvements in cognitive functioning and may serve as a promising target for interventions.
One activity that is known to upregulate BDNF and improve cognitive functioning is aerobic exercise training (AE) [32] [33] [34] [35] , with synthesis and release of BDNF into blood circulation occurring in a dose-response manner [36, 37] . Consistent with these findings, a recent meta-analysis of 29 studies demonstrated increases in BDNF after a single bout of exercise [38] . Likewise, animal research strongly supports the positive influence of AE on cognitive functioning [39] , along with increases in cell proliferation and survival, particularly in the dentate gyrus [40] [41] [42] . AE has also been linked to new blood vessel growth in the motor cortex [43] , the cerebellum [44] , the hippocampus [45] , and the striatum [46] . In humans, an extensive literature supports the beneficial impact of AE on cognition in adolescents, young adults, and older adults [47] [48] [49] [50] . In a meta-analysis of 29 RCTs (n = 2021), AE significantly improved attention, processing speed, executive functioning, and long-term memory, with a trend for working memory [51] . Similarly, imaging studies indicate that AE-related cognitive improvements are mediated by structural and functional brain changes [52] [53] [54] . In summary, extensive literatures on animal and human research converge in supporting the positive influence of AE on cognition [33, 35, [55] [56] [57] , pointing to robust benefits across the mammalian lifespan [33, 34, 56, [58] [59] [60] .
Germaine to SZ, individuals with SZ tend to be highly sedentary, displaying significantly lower rates of physical activity and fitness compared to healthy individuals [61] . For example, individuals with SZ have been found to spend up to 81% of their wake time in sedentary behavior, and 98% of SZ patients have been found to exhibit age-adjusted low aerobic fitness [62] . Consistent with our findings, a number of recent reviews and metaanalyses indicate that AE training is effective in increasing VO2maxindexed aerobic fitness in individuals with SZ [63] [64] [65] [66] [67] , with VO2max improvements ranging from 8 to 38%, and such interventions leading to cognitive benefits. Specifically, a recent meta-analysis of 10 trials (n = 385 individuals with SZ) found AE significantly improved global cognition (g = 0.33), with a higher effect size in the 7 included RCTs (g = 0.43) [68] .
Meta-regression analyses further indicated that AE significantly improved the cognitive domains of working memory, social cognition, and attention/vigilance [68] .
More recently, a number of studies examined the efficacy of AE in improving aspects of daily functioning in people with SZ. Two RCTs that utilized 120-min per week of moderate-to-vigorous AE training observed significant improvements in functional disability and quality of life, as well as reductions in need for care [63, 64] . Firth and colleagues [69] also reported improved social functioning for 31 patients in response to a 10-
week AE intervention, while some RCTs using low-intensity AE compared to a yoga intervention reported increases in social functioning [70, 71] . In another study, Lee et al. [72] In such cases, the participant will continue to receive their previously assigned intervention. Participation in a study with cognitive assessment in the past 3 months Kinect and similar devices as tools for promoting physical activity [82] .
Studies with healthy individuals suggest whole-body exercises using such devices can stimulate moderately intense aerobic activity in adults, with enjoyment rated significantly higher than traditional exercises [83, 84] , thus representing a comparable fitness alternative [85, 86] . In addition to serious adverse events (SAE), we monitor on a weekly basis potential AE-related minor and moderate adverse events including musculoskeletal/soft tissue (muscle soreness, muscle pull/strain, joint pain, falls); cardiovascular (fatigue, dyspnea, chest pain that resolves with rest); and skin-related side-effects (blisters, chafing). Previous studies indicate a minimally small risk of adverse events as part of AE-related interventions [74, 88] . Our screening procedure, the use of a "start low and go slow" strategy, close monitoring of AE intensity, and the presence of a certified exercise trainer aims to minimize the risk of adverse events.
Stretching and Toning (ST)
ST exercises involve static stretching-a series of techniques that gradually lengthen a muscle to an elongated position to the point of tightness or discomfort and maintenance of that position for 30 to Similar to the AE intervention, at the end of the session, the research assistant uploads the data from the HR monitors to a computer and the data management system for processing and review. ST exercises are low impact and present minimal risk for injury. We utilize a monitoring strategy similar to the one used for the AE training program.
Monitoring interventions' delivery and fidelity
A major strength of our protocol is the use of a data management system that allows for near real-time, dynamic monitoring of study participants' attendance and in-session training intensity. We monitor participants in both intervention arms 
EXPERIMENTAL DESIGN
Participants are assessed at three time points: baseline, intervention midpoint (i.e., 6 weeks), and end-of-study upon completion of the intervention (i.e., 12 weeks). The schedule of assessments at all three time points are outlined in [74] indicate that the risk for un-blinding is minimal-only two of 41 subjects were unblinded with no status disclosures during any of the cognitive assessments or clinical and functioning interviews. to rating patients, all raters were trained in administration and scoring of cognitive and clinical assessments whose scores were assessed for accuracy. A complete schedule of assessments is outlined in Table 2 .
ASSESSMENTS

Primary Outcomes
Neurocognitive functioning
The composite score of the MATRICS Consensus Cognitive Battery (MCCB) [90] serves as the primary cognitive outcome measure. The MCCB assesses cognitive function in seven domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The MCCB is sensitive to change, including in response to AE-induced changes in aerobic fitness [74, 91] . The MCCB has been used widely in SZ cognition trials, and allows for comparison to other intervention studies [92] . All tests are administered between 10:00 AM and 12:00 PM to minimize diurnal-related variability in cognitive performance [93] .
Aerobic fitness
Maximal oxygen uptake ( [74, 77] .
Secondary Outcomes
Daily functioning
The The UPSA is a performance-based measure that has reliably demonstrated the ability to predict real-world functioning in schizophrenia [101] ; it has high correlations with measures of personal care skills, interpersonal skills, and community activities [101, 102] , and has demonstrated high sensitivity to functional changes [103] . The SCoRS is a clinicianadministered interview, to both participants and informants, which assesses cognition-related daily functioning. The SCoRS has been used as a co-primary endpoint measure in several phase-2 and phase-3 trials assessing cognition in schizophrenia, and has been permitted by the FDA for pivotal registration trials. It also has exceptional test-retest reliability, strong relation to cognition, and a high sensitivity to treatment [104] [105] [106] .
BDNF
Serum BDNF is measured by ELISA method (R&D Systems, Minneapolis, MN). Intra-and inter-assay variability is 3.8% and 7.6%, respectively.
Sensitivity is <20 pg/mL. The range in healthy people is 6, 186-42, 580 pg/mL. All samples are collected between 9:00 AM and 10:00 AM to reduce diurnal-related variability in BDNF [107, 108] . Samples clot for 60 min at room temperature [107] and is removed after centrifugation at 3200 rpm at 4 °C, then frozen on dry ice and stored at −80 °C until end-of-study.
Samples will be then be express shipped for analyses at the Human J Psychiatry Brain Sci. 2019;4:e190020. https://doi.org/10.20900/jpbs.20190020
Immune Monitoring Center (HIMC) at Icahn School of Medicine at Mount
Sinai in New York.
Exploratory Outcomes
Clinical measures
Diagnoses is determined using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) [108] . The SCID is used to confirm diagnosis of SZ or related disorders and the presence or absence of substance abuse or dependence. Current positive, negative, and general clinical symptoms are indexed using the Positive and Negative Syndrome Scale (PANSS) [109] and the Beck Depression Inventory (BDI-II) [110] .
Measures relevant to weight and physical activity
Data on BMI, abdominal circumference, and blood pressure, as well as Accelerometry assessment is conducted over 7-day epochs using established cut points [112] . we document the use of relevant medications at baseline using a dummy variable, along with increases, no change, decreases, or discontinuation at follow-up assessments (1, 0, −1, or −2, respectively). We also inquire about use of medications that may influence cognition (e.g., antihistamines for allergies) during the 48 hours prior to cognitive and aerobic fitness tests.
Other variables that may impact cognition or treatment response
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We utilize a similar strategy to address medications known to affect biomarkers (e.g., SSRIs on BDNF).
We assess sleep (indexed using an adapted version of the Pittsburgh Sleep Quality Index; PSQI) [113] during the 24 h prior to cognitive testing.
The PSQI has been used extensively in SZ studies [114, 115] . If a participant reports substantial acute sleep loss that is likely to impact an outcome (i.e., <4 h sleep) [116] , assessments are postponed until sleep is restored. We assess smoking using the Fagerström Test for Nicotine Dependence (FTND) [117] , along with the number of cigarettes smoked in the 4 hours prior to tests (nicotine half-life = ~2 h) [118, 119] . The FTND has been used successfully in previous SZ studies [120] .
Anxiety symptoms and alexithymia are measured using the Beck Anxiety Inventory (BAI) [121] and the Toronto Alexithymia Scale (TAS) [122] , respectively. Emotion regulation strategies are measured using the Emotion Regulation Questionnaire (ERQ) [123] ; emotion regulation, which has been observed to change in response to exercise [124] , is also impaired among individuals with SZ and may predict functioning [125] . We assess subjective well-being using the Satisfaction with Life Scale (SWLS) [126] , which has been used in prior SZ studies [127] . Childhood trauma is assessed using the Childhood Trauma Questionnaire (CTQ) [128] ; this is especially critical, given the noted influence of trauma on BDNF [129] .
Finally, we evaluate overall clinical symptomatology using the Clinical Global Impression scale (CGI) [130] , while premorbid intellectual functioning will be determined using the Wechsler Test of Adult Reading (WTAR) [131] .
Cognitive and clinical raters' proficiency
We conducted rater training in administration and scoring of cognitive, clinical, and functioning assessments (i.e., MCCB, SCoRS, SCID and PANSS) prior to study initiation, along with subsequent re-training annually. All raters submit anonymized copies of the first 3 administered protocols (MCCB, UPSA, SCoRS, SLOF, and PANSS), followed by every 5th protocol, to ensure accurate procedures and check for completeness. Additionally, raters regularly discuss potential issues related to administration and scoring of measures with the study PI on an as-needed basis.
Participant reimbursement
The compensation for subjects who complete all research assessments is $260 for seven research visits and two week-long assessments with Actigraphs over 12 weeks ($50 for the baseline, $60 for the 6-week, and $150 for the 12-week assessment). Participants also receive $10 reimbursements for travel expenses for each research visit, as well as for each AE or ST training session they attend (paid weekly). As many individuals with SZ are dependent on limited disability benefits, the reimbursement for travel expenses was implemented to minimize the likelihood that participation in the study will be limited to individuals with J Psychiatry Brain Sci. 2019;4:e190020. https://doi.org/10.20900/jpbs.20190020
higher socioeconomic status or those living in close proximity to study sites.
Sample size calculations
The sample size for the protocol is 200 outpatient individuals with schizophrenia (SZ). We determined sample size based on our primary focus on the treatment effect of cognition, specifically the MCCB total composite score. Prior literature suggests that individuals with SZ score, on average, between 1 and 2.5 standard deviations below average on the MCCB [13, 14, 132, 133] . Thus, we chose a clinically meaningful effect size of 0.50, or half a standard deviation in MCCB score, to be our target effect size for powering the trial. In our earlier pilot study [74] , we found a large 
Protocol deviations
The trial is designed using the intent-to-treat (ITT) principle, including all participants as randomized regardless of protocol violations. However, we will conduct separate modified "per-protocol" analyses, including only individuals who engaged in the interventions and have attended at least one exercise session. Such exclusion is consistent with strategies employed in previous intervention studies [134] .
Statistical analysis and statistical tools
The primary aim of the study is to examine the efficacy of aerobic exercise to improve cognition in people with SZ. Specifically, we hypothesize that:
1. At 12-weeks, participants in the AE training will significantly improve their cognitive functioning compared to ST-controls.
2. Increases in aerobic fitness will predict improvements in cognition.
The secondary aims of the study are to examine the efficacy of aerobic exercise to improve functioning in people with SZ.
1. At 12-weeks, participants in the AE training will significantly improve their daily functioning compared to ST-controls.
The third aim of the study is to examine whether aerobic exerciserelated changes in serum-BDNF mediate changes in cognition in individuals with SZ:
1. At 12-weeks, participants in the AE training will demonstrate significantly larger increases in serum-BDNF compared to ST-controls.
2. AE-induced improvements in cognitive functioning from baseline to 6 weeks to 12 weeks will be mediated by increases in serum-BDNF.
3. AE subjects with a robust early increase in serum-BDNF (measured at 6 weeks) will display enhanced 12-week cognitive improvements compared to those with a gradual response.
Additionally, we will explore the impact of potential biologically relevant covariates (e.g., sex, age, BMI), as well as intervention characteristics (e.g., fidelity with AE training intensity), on key outcome variables. Recent reports have linked cognitive functioning to inflammation markers [135, 136] , as well as other neurotrophins, both of which have been found to be susceptible to regulation by physical activity.
Taking advantage of the present study's infrastructure, we will employ an analytic plan similar to the one used for BDNF and explore the links between changes in aerobic fitness, inflammation markers (TNF-α, IL-6, CRP), other neurotrophins (NGF, NT-3, NT-4), and improvements in cognitive functioning.
We will conduct all primary analyses on an ITT basis, such that all randomized participants will be analyzed according to the treatment they were assigned regardless of adherence to treatment. We will also perform statistical analyses controlling for fidelity level to training intensity, which will account for intervention adherence. Main statistical analyses will include variants of mixed effects regressions in order to model changes in cognition, functioning, and serum-BDNF levels as a function of time, treatment group, interaction of time-by-treatment group, and site.
Additionally, we will use mixed effects regressions to assess changes in cognition predicted by contemporaneous change in aerobic fitness (indexed using VO2max tests), controlling for treatment group and other J Psychiatry Brain Sci. 2019;4:e190020. https://doi.org/10.20900/jpbs.20190020
Journal of Psychiatry and Brain Science 20 of 33 covariates. To assess potential mediation of serum-BDNF on the association between AE and cognition, we will fit a structural equation model with changes in serum-BDNF from baseline to 6-weeks as mediators of the relationship between AE intervention and early changes in cognition from baseline to 6-weeks, as well as later changes in cognition from 6-to 12-weeks. Additionally, we will use regression to estimate the association between continuous measures of training intensity and changes in cognition. We will also include sex, age, and baseline BMI as potential moderators of treatment effect by including interactions with treatment in analyses. We will analyze data using R, SAS version 9.4, and/or MPlus verison 8.3 [137] .
Ethical considerations
The trial is approved by the Institutional Review Boards (IRBs) of Icahn At each site, the site PI will contact clinicians and inform them about the study, who will subsequently describe the study to potential participants and evaluate their interest. If the patient is interested and willing, a member of the research team will describe the study in more detail and invite them to enroll. As part of the informed consent process, the study rationale and methods will be described in detail and any questions will be answered. We will assure patients that participation is voluntary, they can withdraw at any time, and they will receive ordinary treatment whether or not they choose to participate. All prospective patients will be judged clinically competent to give written informed consent. We will obtain informed consent from all participants prior to study participation, using a consent form approved by the site's Institutional Review Board.
We will administer assessments over multiple days, in order to avoid placing unnecessary strain on the individual. Also, the participant's targeted weekly HR will be based on the individual's baseline physical fitness level (i.e., minimal and maximal HR), thereby ensuring that the intervention's targeted physical intensity level is safe to engage in.
Participants who experience discomfort or chest pain while exercising will receive immediate examination by the study physician, and will ensure that the participant receives proper medical intervention, if necessary.
Adverse events
The for ethical or safety purposes will have their participation discontinued.
In such cases, participants will be offered other treatment. Additionally, all participants will continue to receive their usual mental health treatment.
Emergency procedures
To minimize risk of medical emergencies, patients with untreated hypertension, cardiac disease, or other medical conditions that may interfere with study participation (e.g., malignancy, liver or renal impairment) will be excluded from the study. The study physician will perform a medical examination and review participant ECG and blood tests prior to study inclusion. During exercise sessions, if the participant reports chest pain, the session will be discontinued, and the study physician will be notified immediately. The physician will then evaluate the participant and make the determination for potential additional medical intervention. If chest pain resolves on its own but is suspicious for cardiac pain, then follow-up will be arranged with the participant's general medical physician; no further exercise sessions will be held for the patient until after this evaluation. If chest pain resulting from exercise does not resolve quickly, then emergency personnel will be notified and transfer to an emergency room ensured.
DISCUSSION
Converging lines of preclinical and clinical research support the premise that AE potentially improves cognition and subsequent functional outcomes in individuals diagnosed with SZ. Specifically, evidence from our previous pilot study [74] , as well as other AE studies in SZ [63, 64, 69, [138] [139] [140] [141] [142] [143] [144] [145] suggest that AE training is an efficacious, non-stigmatizing intervention for improving cognitive functioning in individuals with SZ. However, the extant AE and cognition in SZ literature has a number of weaknesses, which the current trial aims to address. In the present study, 12-weeks of AE training is compared to a ST control intervention of similar duration, which has been previously demonstrated to improve cognition and functioning [74] . We aim to recruit 200 individuals diagnosed with SZ or related disorders, thereby establishing the first fully powered comprehensive study assessing the efficacy of AE to improve cognitive functioning in SZ. We will use well-validated measures of cognition known to assess multiple cognitive sub-domains, as well as VO2max tests to assess aerobic fitness; these assessments will be administered at baseline (prior to training), midway into training (6-weeks), and immediately upon completion of training (12-weeks). Secondary outcome measures will include various measures of daily functioning (including self-report, informant, and clinician-based assessments), as well as serum-BDNF measurement to explore the potential mediating influence of BDNF on the relationship between AE and cognition in SZ. Regarding the exercise intervention, in addition to traditional exercise equipment, our study will J Psychiatry Brain Sci. 2019;4:e190020. https://doi.org/10.20900/jpbs.20190020 use active-play video games, which has proven successful in increasing aerobic fitness [85] , specifically in this population [74] . Additionally, we will assess training fidelity not only through exercise training attendance, but also by tracking training intensity by utilizing HR monitors during each exercise session to quantify in-session intervention delivery. If we find that AE improves cognitive performance, aerobic fitness, and daily functioning compared to ST, it may have significant implications for future treatment of patients with SZ. If confirmed, the results of this trial may provide support for the development of novel behavioral treatments to treat cognitive deficits in individuals with SZ, as well as provide information about the mechanisms underlying cognition deficits in this population.
In the continued absence of medications that effectively improve cognition in patients with SZ, persistent cognitive deficits adversely affect the prognosis and functioning of many affected individuals. The present study will provide information about a novel AE strategy to improve cognition, and subsequent functional outcome, that can be widely implemented and thus have a significant public health impact.
Information to be obtained on mechanism of action will have the potential to inform the development and improvement of future treatments of cognitive deficits in SZ.
Trial status
Recruitment began at the Mount Sinai site in April 2018, with recruitment at other sites initiating in May 2018. As of November 2019, a total of 64 participants were enrolled in the trial, with 45 participants randomized.
